KR101276422B1 - Ｈｉｖ 유입 억제제의 중합체-기재 조성물 및 콘쥬게이트 - Google Patents

Ｈｉｖ 유입 억제제의 중합체-기재 조성물 및 콘쥬게이트 Download PDF

Info

Publication number
KR101276422B1
KR101276422B1 KR1020067019107A KR20067019107A KR101276422B1 KR 101276422 B1 KR101276422 B1 KR 101276422B1 KR 1020067019107 A KR1020067019107 A KR 1020067019107A KR 20067019107 A KR20067019107 A KR 20067019107A KR 101276422 B1 KR101276422 B1 KR 101276422B1
Authority
KR
South Korea
Prior art keywords
conjugate
polymer
delete delete
poly
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020067019107A
Other languages
English (en)
Korean (ko)
Other versions
KR20060130225A (ko
Inventor
마이클 디 벤틀리
쉬안 자오
헤롤드 자페
Original Assignee
넥타르 테라퓨틱스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 넥타르 테라퓨틱스 filed Critical 넥타르 테라퓨틱스
Publication of KR20060130225A publication Critical patent/KR20060130225A/ko
Application granted granted Critical
Publication of KR101276422B1 publication Critical patent/KR101276422B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/02—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
    • C08G63/12—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from polycarboxylic acids and polyhydroxy compounds
    • C08G63/46—Polyesters chemically modified by esterification
    • C08G63/48—Polyesters chemically modified by esterification by unsaturated higher fatty oils or their acids; by resin acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Polymers & Plastics (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020067019107A 2004-03-15 2005-03-15 Ｈｉｖ 유입 억제제의 중합체-기재 조성물 및 콘쥬게이트 Expired - Fee Related KR101276422B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55314604P 2004-03-15 2004-03-15
US60/553,146 2004-03-15
PCT/US2005/008632 WO2005089805A2 (en) 2004-03-15 2005-03-15 Polymer-based compositions and conjugates of hiv entry inhibitors

Publications (2)

Publication Number Publication Date
KR20060130225A KR20060130225A (ko) 2006-12-18
KR101276422B1 true KR101276422B1 (ko) 2013-06-19

Family

ID=34994420

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067019107A Expired - Fee Related KR101276422B1 (ko) 2004-03-15 2005-03-15 Ｈｉｖ 유입 억제제의 중합체-기재 조성물 및 콘쥬게이트

Country Status (9)

Country Link
US (1) US9446139B2 (enExample)
EP (1) EP1725262B1 (enExample)
JP (1) JP4805911B2 (enExample)
KR (1) KR101276422B1 (enExample)
CN (1) CN101132812A (enExample)
AU (1) AU2005222641B2 (enExample)
CA (1) CA2558583C (enExample)
MX (1) MXPA06010505A (enExample)
WO (1) WO2005089805A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE444984T1 (de) * 2002-12-31 2009-10-15 Nektar Therapeutics Al Corp Hydrolysestabile maleimidendgruppen-enthaltende polymere
US7432331B2 (en) * 2002-12-31 2008-10-07 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
EP1708734A4 (en) * 2004-01-07 2009-06-17 Trimeris Inc PEPTIDES DERIVED FROM HIV GP41 HR2 AND THEIR USE IN THERAPY TO INHIBIT THE TRANSMISSION OF HUMAN IMMUNODICIENCY VIRUS
DE102004031258A1 (de) * 2004-06-29 2006-02-09 Jennissen, Herbert P., Prof. Dr. Proteinhybride mit polyhydroxyaromatischen Aminosäure-Epitopen
EP1885403B1 (en) * 2005-04-12 2013-05-08 Nektar Therapeutics Poly(ethyleneglycol) conjugates of Lysostaphin
PT1989220E (pt) * 2006-02-02 2012-03-23 Trimeris Inc Péptidos inibidores de fusão de hiv com propriedades biológicas melhoradas
US7671067B2 (en) * 2006-02-09 2010-03-02 Enzon Pharmaceuticals, Inc. Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecin
US7462627B2 (en) * 2006-02-09 2008-12-09 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
MX2008010841A (es) 2006-02-21 2008-10-27 Nektar Therapeutics Al Corp Polimeros degradables segmentados y conjugados hechos de los mismos.
US20090285780A1 (en) * 2006-05-24 2009-11-19 Chyi Lee Peg linker compounds and biologically active conjugates thereof
EP2054074B8 (en) 2006-08-04 2014-11-12 Prolong Pharmaceuticals, LLC Modified erythropoietin
BRPI0807232A2 (pt) * 2007-02-09 2014-04-29 Enzon Pharmaceuticals Inc Tratamento de cânceres resistentes ou refratários com conjugados poliméricos multi-braços de 7-etil-10-hidroxicamptotecina
EP2134181A4 (en) * 2007-02-28 2011-09-28 Serina Therapeutics Inc ACTIVATED POLYOXAZOLINES AND COMPOSITION COMPRISING THE SAME
US20140011964A1 (en) 2007-02-28 2014-01-09 Serina Therapeutics, Inc. Activated Polyoxazolines and Conjugates and Compositions Comprising the Same
CA2682848A1 (en) * 2007-04-03 2008-10-16 Trimeris, Inc. Novel formulations for delivery of antiviral peptide therapeutics
BRPI0817697A2 (pt) * 2007-09-25 2015-04-07 Trimeris Inc Método de síntese de um peptídeo, conjunto de fragmentos de peptídeo, e, peptídeo
TW201010732A (en) * 2008-08-29 2010-03-16 Enzon Pharmaceuticals Inc Method of treating RAS associated cancer
CN102215688A (zh) * 2008-10-21 2011-10-12 安龙制药公司 用7-乙基-10-羟基喜树碱的多臂聚合物对神经母细胞瘤的治疗
HUE043689T2 (hu) * 2009-11-18 2019-09-30 Nektar Therapeutics Polimer-gyógyszer savas sói
WO2011084458A2 (en) * 2009-12-15 2011-07-14 The Johns Hopkins University Polymer-based compositions and methods for treatment of peritoneal disorders
US20110295365A1 (en) * 2010-05-28 2011-12-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-viral compositions and methods for administration
WO2013158454A2 (en) * 2012-04-18 2013-10-24 Siemens Healthcare Diagnostics Inc. Compounds and methods for preparation of conjugate reagents
CN104109240A (zh) * 2014-07-13 2014-10-22 成都市绿科华通科技有限公司 一种可作为药物载体的多孔聚乙二醇的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001003723A1 (en) * 1999-07-09 2001-01-18 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US20010011115A1 (en) 1998-03-12 2001-08-02 J. Milton Harris Poly (ethylene glycol) derivatives with proximal reactive groups
US6413507B1 (en) * 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992013947A1 (en) 1991-02-08 1992-08-20 Progenics Pharmaceuticals, Inc. CD4-GAMMA2 AND CD4-IgG2 CHIMERAS
US5446090A (en) * 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5792462A (en) * 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
US20040228869A1 (en) 1998-12-16 2004-11-18 Progenics Pharmaceuticals, Inc. Synergistic inhibition of HIV-1 fusion and attachment, compositions and antibodies thereto
US6469136B1 (en) 1999-07-07 2002-10-22 Trimeris, Inc. Methods and composition for peptide synthesis
US6541020B1 (en) 1999-07-09 2003-04-01 Trimeris, Inc. Methods and compositions for administration of therapeutic reagents
AU2001238595A1 (en) 2000-02-22 2001-09-03 Shearwater Corporation N-maleimidyl polymer derivatives
WO2001064710A2 (en) 2000-02-29 2001-09-07 Progenics Pharmaceuticals, Inc. Sulfated ccr5 peptides for hiv-1 infection
CN100352837C (zh) * 2002-07-24 2007-12-05 弗·哈夫曼-拉罗切有限公司 聚乙二醇化的t1249多肽
DE60335111D1 (de) * 2002-07-24 2011-01-05 Hoffmann La Roche Pegyliertes t20-polypeptid
AU2003258518B2 (en) 2002-07-24 2007-01-18 F. Hoffmann-La Roche Ag Polyalkylene glycol acid additives
EP1546235B1 (en) * 2002-09-09 2021-10-20 Nektar Therapeutics Water-soluble polymer alkanals
US7556813B2 (en) 2002-09-27 2009-07-07 Trimeris, Inc. Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides
CA2508015C (en) 2002-12-30 2012-04-03 Nektar Therapeutics Al, Corporation Multi-arm polypeptide-poly(ethylene glycol) block copolymers as drug delivery vehicles
AU2003300140A1 (en) * 2002-12-31 2004-07-29 Nektar Therapeutics Al, Corporation Methods for the formation of hydrogels using thiosulfonate compositions and uses thereof
AU2003300139B2 (en) * 2002-12-31 2008-08-28 Nektar Therapeutics Maleamic acid polymer derivatives and their bioconjugates
DE602004029646D1 (en) * 2003-01-06 2010-12-02 Nektar Therapeutics San Carlos Thiolselektive wasserlösliche polymerderivate
SI1596887T1 (sl) * 2003-02-26 2022-05-31 Nektar Therapeutics Konjugati polimer-del faktorja VIII
KR101128320B1 (ko) 2003-05-23 2012-04-12 넥타르 테라퓨틱스 아미도카르보네이트 연결기를 갖는 ｐｅｇ 유도체
EP1734994A1 (en) 2004-03-15 2006-12-27 Trimeris, Inc. Site-specific chemical modification of hiv gp41-derived peptides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010011115A1 (en) 1998-03-12 2001-08-02 J. Milton Harris Poly (ethylene glycol) derivatives with proximal reactive groups
WO2001003723A1 (en) * 1999-07-09 2001-01-18 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6413507B1 (en) * 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)

Also Published As

Publication number Publication date
US20050226843A1 (en) 2005-10-13
US9446139B2 (en) 2016-09-20
AU2005222641A1 (en) 2005-09-29
JP4805911B2 (ja) 2011-11-02
KR20060130225A (ko) 2006-12-18
MXPA06010505A (es) 2006-12-19
CA2558583A1 (en) 2005-09-29
WO2005089805A3 (en) 2007-07-19
EP1725262B1 (en) 2021-05-26
CN101132812A (zh) 2008-02-27
JP2007529539A (ja) 2007-10-25
EP1725262A2 (en) 2006-11-29
WO2005089805A2 (en) 2005-09-29
AU2005222641B2 (en) 2011-04-07
CA2558583C (en) 2013-07-09

Similar Documents

Publication Publication Date Title
KR101276422B1 (ko) Ｈｉｖ 유입 억제제의 중합체-기재 조성물 및 콘쥬게이트
US20220143201A1 (en) Composition comprising a polymeric reagent
EP1885403B1 (en) Poly(ethyleneglycol) conjugates of Lysostaphin
AU2022268401A1 (en) Conjugates of an IL-2 moiety and a polymer
AU2016228555B2 (en) Conjugates of an IL-7 moiety and a polymer
CA2942571A1 (en) Conjugates of an il-15 moiety and a polymer
AU2004215912A1 (en) Polymer-factor VIII moiety conjugates
JP6626045B2 (ja) コリンエステラーゼ部分とポリマーとのコンジュゲート
US8905235B2 (en) Polymeric reagents comprising a terminal vinylic group and conjugates formed therefrom
JP7618383B2 (ja) オキシム含有リンケージを有する第ｖｉｉｉ因子部分のコンジュゲート

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20160330

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20170330

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20180329

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20190327

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20230613

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20230613